Research ArticleOriginal Article
Open Access

The risk factors for cardiovascular disease and chronic kidney disease in patients with nonalcoholic fatty liver disease in Saudi Arabia

Walaa Mohammedsaeed, Abdullah Al Malki and Salma Alsayed
Saudi Medical Journal May 2025, 46 (5) 478-490; DOI: https://doi.org/10.15537/smj.2025.46.5.20240901

References

  1. 1.↵
    1. Rector RS,
    2. Thyfault JP,
    3. Wei Y,
    4. Ibdah JA.
    Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol 2008; 14: 185-192.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Akbar DH,
    2. Kawther AH.
    Nonalcoholic fatty liver disease in Saudi type 2 diabetic subjects attending a medical outpatient clinic: prevalence and general characteristics. Diabetes Care 2003; 26: 3351-3352.
    OpenUrlFREE Full Text
  3. 3.
    1. Al-Quorain A,
    2. Satti MB,
    3. al-Hamdan AR,
    4. al-Gindan Y,
    5. Ibrahim E,
    6. Khatib R, et al.
    Pattern of chronic liver disease in the eastern province of Saudi Arabia. A hospital-based clinicopathological study. Trop Geogr Med 1994; 46: 358-360.
    OpenUrlPubMed
  4. 4.↵
    1. El-Hassan AY,
    2. Ibrahim EM,
    3. al-Mulhim FA,
    4. Nabhan AA,
    5. Chammas MY
    . Fatty infiltration of the liver: analysis of prevalence, radiological and clinical features and influence on patient management. Br J Radiol 1992; 65: 774-778.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Al Dawish MA,
    2. Robert AA,
    3. Braham R,
    4. Al Hayek AA,
    5. Al Saeed A,
    6. Ahmed RA, et al.
    Diabetes mellitus in Saudi Arabia: a review of the recent literature. Curr Diabetes Rev 2016; 12: 359-368.
    OpenUrlPubMed
  6. 6.↵
    1. Al-Nozha MM,
    2. Al-Mazrou YY,
    3. Al-Maatouq MA,
    4. Arafah MR,
    5. Khalil MZ,
    6. Khan NB, et al.
    Obesity in Saudi Arabia. Saudi Med J 2005; 26: 824-829.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Fraser SD,
    2. Blakeman T.
    Chronic kidney disease: identification and management in primary care. Pragmat Obs Res 2016; 7: 21-32.
    OpenUrlPubMed
  8. 8.↵
    1. Fraser SD,
    2. Parkes J,
    3. Culliford D,
    4. Santer M,
    5. Roderick PJ.
    Timeliness in chronic kidney disease and albuminuria identification: a retrospective cohort study. BMC Fam Pract 2015; 16: 18.
    OpenUrlCrossRefPubMed
  9. 9.
    1. Lamb EJ,
    2. MacKenzie F,
    3. Stevens PE.
    How should proteinuria be detected and measured? Ann Clin Biochem 2009; 46: 205-217.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. White SL,
    2. Yu R,
    3. Craig JC,
    4. Polkinghorne KR,
    5. Atkins RC,
    6. Chadban SJ.
    Diagnostic accuracy of urine dipsticks for detection of albuminuria in the general community. Am J Kidney Dis 2011; 58: 19-28.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Cheung A,
    2. Ahmed A.
    Nonalcoholic fatty liver disease and chronic kidney disease: a review of links and risks. Clin Exp Gastroenterol 2021; 14: 457-465.
    OpenUrlPubMed
  12. 12.↵
    1. Musso G,
    2. Gambino R,
    3. Tabibian JH,
    4. Ekstedt M,
    5. Kechagias S,
    6. Hamaguchi M, et al.
    Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014; 11: e1001680.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Byrne CD,
    2. Targher G.
    NAFLD: a multisystem disease. J Hepatol 2015; 62: S47-S64.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Wilechansky RM,
    2. Pedley A,
    3. Massaro JM,
    4. Hoffmann U,
    5. Benjamin EJ,
    6. Long MT.
    Relations of liver fat with prevalent and incident chronic kidney disease in the Framingham Heart Study: a secondary analysis. Liver Int 2019; 39: 1535-1544.
    OpenUrlPubMed
  15. 15.↵
    1. Al-Rubeaan K,
    2. Bawazeer N,
    3. Al Farsi Y,
    4. Youssef AM,
    5. Al-Yahya AA,
    6. AlQumaidi H, et al.
    Prevalence of metabolic syndrome in Saudi Arabia - a cross sectional study. BMC Endocr Disord 2018; 18: 16.
    OpenUrlPubMed
  16. 16.↵
    1. Alswat K,
    2. Aljumah AA,
    3. Sanai FM,
    4. Abaalkhail F,
    5. Alghamdi M,
    6. Al Hamoudi WK, et al.
    Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030. Saudi J Gastroenterol 2018; 24: 211-219.
    OpenUrlPubMed
  17. 17.↵
    1. Younossi ZM,
    2. Koenig AB,
    3. Abdelatif D,
    4. Fazel Y,
    5. Henry L,
    6. Wymer M.
    Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Hydes T,
    2. Buchanan R,
    3. Kennedy OJ,
    4. Fraser S,
    5. Parkes J,
    6. Roderick P.
    Systematic review of the impact of non-alcoholic fatty liver disease on mortality and adverse clinical outcomes for individuals with chronic kidney disease. BMJ Open 2020; 10: e040970.
    OpenUrlPubMed
  19. 19.↵
    1. Kogiso T,
    2. Moriyoshi Y,
    3. Shimizu S,
    4. Nagahara H,
    5. Shiratori K.
    High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population. J Gastroenterol 2009; 44: 313-321.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Mirzadeh M,
    2. Nikparvar M,
    3. Rafati S,
    4. Kheirandish M,
    5. Azarbad A,
    6. Sheybani-Arani M, et al.
    Atherogenic index of plasma as a predictor of coronary artery disease: a cohort study in south of Iran. Egypt Heart J 2024; 76: 65.
    OpenUrlPubMed
  21. 21.↵
    1. Gansevoort RT,
    2. Matsushita K,
    3. van der Velde M,
    4. Astor BC,
    5. Woodward M,
    6. Levey AS, et al.
    Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 2011; 80: 93-104.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Nuttall FQ.
    Body mass index: obesity, BMI, and health: a critical review. Nutr Today 2015; 50: 117-128.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Khov N,
    2. Sharma A,
    3. Riley TR.
    Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20: 6821-6825.
    OpenUrlPubMed
  24. 24.↵
    1. Kammar-García A,
    2. López-Moreno P,
    3. Hernández-Hernández ME,
    4. Ortíz-Bueno AM,
    5. Martínez-Montaño MLC.
    Atherogenic index of plasma as a marker of cardiovascular risk factors in Mexicans aged 18-22 years. Proc (Bayl Univ Med Cent) 2020; 34: 22-27.
    OpenUrlPubMed
  25. 25.↵
    1. Mosca S,
    2. Araújo G,
    3. Costa V,
    4. Correia J,
    5. Bandeira A,
    6. Martins E, et al.
    Dyslipidemia diagnosis and treatment: risk stratification in children and adolescents. J Nutr Metab 2022; 2022: 4782344.
    OpenUrlPubMed
  26. 26.↵
    1. Mantovani A,
    2. Csermely A,
    3. Petracca G,
    4. Beatrice G,
    5. Corey KE,
    6. Simon TG, et al.
    Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021; 6: 903-913.
    OpenUrlPubMed
  27. 27.↵
    1. Niroumand S,
    2. Khajedaluee M,
    3. Khadem-Rezaiyan M,
    4. Abrishami M,
    5. Juya M,
    6. Khodaee G, et al.
    Atherogenic Index of Plasma (AIP): a marker of cardiovascular disease. Med J Islam Repub Iran 2015; 29: 240.
    OpenUrlPubMed
  28. 28.↵
    1. Alenezi YM,
    2. Harris R,
    3. Morling J,
    4. Card T.
    Prevalence of non-alcoholic fatty liver disease (NAFLD) in Saudi Arabia: systematic review and meta-analysis. Cureus 2023; 15: e40308.
    OpenUrlPubMed
  29. 29.↵
    1. Al-Rubeaan K,
    2. Bawazeer N,
    3. Al Farsi Y,
    4. Youssef AM,
    5. Al-Yahya AA,
    6. AlQumaidi H, et al.
    Prevalence of metabolic syndrome in Saudi Arabia - a cross sectional study. BMC Endocr Disord 2018; 18: 16.
    OpenUrlPubMed
  30. 30.↵
    1. Przybyszewski EM,
    2. Targher G,
    3. Roden M,
    4. Corey KE.
    Nonalcoholic fatty liver disease and cardiovascular disease. Clin Liver Dis (Hoboken) 2021; 17: 19-22.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. DeFilippis AP,
    2. Blaha MJ,
    3. Martin SS,
    4. Reed RM,
    5. Jones SR,
    6. Nasir K, et al.
    Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic study of Atherosclerosis. Atherosclerosis 2013; 227: 429-436.
    OpenUrlCrossRefPubMed
  32. 32.
    1. Duell PB,
    2. Welty FK,
    3. Miller M,
    4. Chait A,
    5. Hammond G,
    6. Ahmad Z, et al.
    Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol 2022; 42: e168-e185.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Allen AM,
    2. Therneau TM,
    3. Larson JJ,
    4. Coward A,
    5. Somers VK,
    6. Kamath PS.
    Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study. Hepatology 2018; 67: 1726-1736.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Stahl EP,
    2. Dhindsa DS,
    3. Lee SK,
    4. Sandesara PB,
    5. Chalasani NP,
    6. Sperling LS.
    Nonalcoholic fatty liver disease and the heart: JACC atate-of-the-art review. J Am Coll Cardiol 2019; 73: 948-963.
    OpenUrlFREE Full Text
  35. 35.↵
    1. Francque SM,
    2. van der Graaff D,
    3. Kwanten WJ.
    Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J Hepatol 2016; 65: 425-443.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Ismaiel A,
    2. Dumitraşcu DL.
    Cardiovascular risk in fatty liver disease: the liver-heart axis-literature review. Front Med (Lausanne) 2019; 6: 202.
    OpenUrlPubMed
  37. 37.↵
    1. Kasper P,
    2. Martin A,
    3. Lang S,
    4. Kütting F,
    5. Goeser T,
    6. Demir M, et al.
    NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol 2021; 110: 921-937.
    OpenUrlCrossRefPubMed
  38. 38.
    1. Brunt EM,
    2. Neuschwander-Tetri BA,
    3. Oliver D,
    4. Wehmeier KR,
    5. Bacon BR.
    Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum Pathol 2004; 35: 1070-1082.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Chalasani N,
    2. Younossi Z,
    3. Lavine JE,
    4. Charlton M,
    5. Cusi K,
    6. Rinella M, et al.
    The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-357.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Angulo P,
    2. Kleiner DE,
    3. Dam-Larsen S,
    4. Adams LA,
    5. Bjornsson ES,
    6. Charatcharoenwitthaya P, et al.
    Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149: 389-397.
    OpenUrlCrossRefPubMed
  41. 41.
    1. Ekstedt M,
    2. Franzén LE,
    3. Mathiesen UL,
    4. Thorelius L,
    5. Holmqvist M,
    6. Bodemar G, et al.
    Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    1. Haflidadottir S,
    2. Jonasson JG,
    3. Norland H,
    4. Einarsdottir SO,
    5. Kleiner DE,
    6. Lund SH, et al.
    Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterol 2014; 14: 166.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Marcuccilli M,
    2. Chonchol M.
    NAFLD and chronic kidney disease. Int J Mol Sci 2016; 17: 562.
    OpenUrlPubMed
  44. 44.↵
    1. Ziolkowska S,
    2. Binienda A,
    3. Jabłkowski M,
    4. Szemraj J,
    5. Czarny P.
    The interplay between insulin resistance, inflammation, oxidative stress, base excision repair and metabolic syndrome in nonalcoholic fatty liver disease. Int J Mol Sci 2021; 22: 11128.
    OpenUrlPubMed
  45. 45.↵
    1. Sproston NR,
    2. Ashworth JJ.
    Role of C-reactive protein at sites of inflammation and infection. Front Immunol 2018; 9: 754.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. You YK,
    2. Huang XR,
    3. Chen HY,
    4. Lyu XF,
    5. Liu HF,
    6. Lan HY.
    C-reactive protein promotes diabetic kidney disease in db/db mice via the CD32b-Smad3-mTOR signaling pathway. Sci Rep 2016; 6: 26740.
    OpenUrlPubMed
  47. 47.↵
    1. Babusik P,
    2. Bilal M,
    3. Duris I.
    Nonalcoholic fatty liver disease of 2 ethnic groups in Kuwait: comparison of prevalence and risk factors. Med Princ Pract 2012; 21: 56-62.
    OpenUrlPubMed
  48. 48.↵
    1. Paudel MS,
    2. Tiwari A,
    3. Mandal A,
    4. Shrestha B,
    5. Kafle P,
    6. Chaulagai B, et al.
    Metabolic syndrome in patients with non-alcoholic fatty liver disease: a community based cross-sectional study. Cureus 2019; 11: e4099.
    OpenUrlPubMed
  49. 49.↵
    1. Thiele JR,
    2. Zeller J,
    3. Bannasch H,
    4. Stark GB,
    5. Peter K,
    6. Eisenhardt SU.
    Targeting C-reactive protein in inflammatory disease by preventing conformational changes. Mediators Inflamm 2015; 2015: 372432.
    OpenUrlPubMed
  50. 50.↵
    1. Devi J,
    2. Raees A,
    3. Butt AS.
    Redefining non-alcoholic fatty liver disease to metabolic associated fatty liver disease: is this plausible? World J Hepatol 2022; 14: 158-167.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords